Sean Kraus1, Thomas Kolman1, Austin Yeung1, Dustin Deming2,3,4,5. 1. Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of WI-Madison, Madison, WI, USA. 2. Division of Hematology, Oncology and Palliative Care, Department of Medicine, University of WI-Madison, Madison, WI, USA. ddeming@medicine.wisc.edu. 3. University of Wisconsin Carbone Cancer Center, Madison, WI, USA. ddeming@medicine.wisc.edu. 4. McArdle Laboratory for Cancer Research, Department of Oncology, University of WI-Madison, Madison, WI, USA. ddeming@medicine.wisc.edu. 5. 6507 WI Institutes for Medical Research, 1111 Highland Ave, Madison, WI, 53705, USA. ddeming@medicine.wisc.edu.
Abstract
PURPOSE OF REVIEW: To evaluate the clinical potential of chemokine receptor antagonists for the treatment of patients with cancer. RECENT FINDINGS: Chemokine receptors and their ligands can have a significant impact on the infiltration of cells into the tumor microenvironment. The receptors are increasingly being investigated as targets for the treatment of cancers. Recent studies are demonstrating the promise of chemokine receptor antagonists in this setting. There are many chemokine receptors, and each can have different functions depending on the cellular context. Targeting chemokine receptors is a promising strategy in both pre-clinical research and clinical trials. Inhibiting chemokine receptors that either recruit suppressive cells or improve cancer mobility and viability while sparing those necessary for proper immune trafficking may prove to dramatically improve treatment responses. Further research in this area is warranted and has the potential to dramatically improve patient outcomes.
PURPOSE OF REVIEW: To evaluate the clinical potential of chemokine receptor antagonists for the treatment of patients with cancer. RECENT FINDINGS: Chemokine receptors and their ligands can have a significant impact on the infiltration of cells into the tumor microenvironment. The receptors are increasingly being investigated as targets for the treatment of cancers. Recent studies are demonstrating the promise of chemokine receptor antagonists in this setting. There are many chemokine receptors, and each can have different functions depending on the cellular context. Targeting chemokine receptors is a promising strategy in both pre-clinical research and clinical trials. Inhibiting chemokine receptors that either recruit suppressive cells or improve cancer mobility and viability while sparing those necessary for proper immune trafficking may prove to dramatically improve treatment responses. Further research in this area is warranted and has the potential to dramatically improve patient outcomes.
Authors: Sarah Greene; Yvette Robbins; Wojciech K Mydlarz; Angel P Huynh; Nicole C Schmitt; Jay Friedman; Lucas A Horn; Claudia Palena; Jeffrey Schlom; Dean Y Maeda; John A Zebala; Paul E Clavijo; Clint Allen Journal: Clin Cancer Res Date: 2019-12-17 Impact factor: 12.531
Authors: Nina Hastrup; Sauzanne Khalilieh; David C Dale; Lars G Hanson; Peter Magnusson; Anjela Tzontcheva; Jack Tseng; Susan Huyck; Elizabeth Rosenberg; Kim Krogsgaard Journal: Cytokine Date: 2015-02-04 Impact factor: 3.861
Authors: Hideaki Ijichi; Anna Chytil; Agnieszka E Gorska; Mary E Aakre; Brian Bierie; Motohisa Tada; Dai Mohri; Koji Miyabayashi; Yoshinari Asaoka; Shin Maeda; Tsuneo Ikenoue; Keisuke Tateishi; Christopher V E Wright; Kazuhiko Koike; Masao Omata; Harold L Moses Journal: J Clin Invest Date: 2011-09-19 Impact factor: 14.808
Authors: Richard B Moss; Sunil J Mistry; Michael W Konstan; Joseph M Pilewski; Eitan Kerem; Ruth Tal-Singer; Aili L Lazaar Journal: J Cyst Fibros Date: 2012-09-17 Impact factor: 5.482
Authors: Guiquan Zhu; H Hannah Yan; Yanli Pang; Jiang Jian; Bhagelu R Achyut; Xinhua Liang; Jonathan M Weiss; Robert H Wiltrout; M Christine Hollander; Li Yang Journal: Oncotarget Date: 2015-12-22